- Home
- GWRE vs RPRX Comparison
GWRE vs RPRX Comparison
Compare GWRE & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRE
- RPRX
- Stock Information
- Founded
- GWRE 2001
- RPRX 1996
- Country
- GWRE United States
- RPRX United States
- Employees
- GWRE N/A
- RPRX N/A
- Industry
- GWRE Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GWRE Technology
- RPRX Health Care
- Exchange
- GWRE Nasdaq
- RPRX Nasdaq
- Market Cap
- GWRE 20.6B
- RPRX 16.2B
- IPO Year
- GWRE 2012
- RPRX 2020
- Fundamental
- Price
- GWRE $213.69
- RPRX $39.45
- Analyst Decision
- GWRE Buy
- RPRX Strong Buy
- Analyst Count
- GWRE 14
- RPRX 3
- Target Price
- GWRE $270.77
- RPRX $46.00
- AVG Volume (30 Days)
- GWRE 708.4K
- RPRX 3.9M
- Earning Date
- GWRE 12-04-2025
- RPRX 11-05-2025
- Dividend Yield
- GWRE N/A
- RPRX 2.23%
- EPS Growth
- GWRE N/A
- RPRX N/A
- EPS
- GWRE 0.81
- RPRX 1.75
- Revenue
- GWRE $1,202,459,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- GWRE $18.42
- RPRX $36.16
- Revenue Next Year
- GWRE $15.10
- RPRX $2.04
- P/E Ratio
- GWRE $264.60
- RPRX $22.53
- Revenue Growth
- GWRE 22.64
- RPRX 3.70
- 52 Week Low
- GWRE $165.09
- RPRX $24.05
- 52 Week High
- GWRE $272.60
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- GWRE 33.12
- RPRX 60.31
- Support Level
- GWRE $214.34
- RPRX $38.82
- Resistance Level
- GWRE $223.28
- RPRX $40.01
- Average True Range (ATR)
- GWRE 6.44
- RPRX 1.19
- MACD
- GWRE -1.34
- RPRX 0.05
- Stochastic Oscillator
- GWRE 12.38
- RPRX 66.81
About GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.